NeuroSense Therapeutics (NRSN)
(Delayed Data from NSDQ)
$1.23 USD
-0.03 (-2.38%)
Updated Apr 26, 2024 03:59 PM ET
After-Market: $1.23 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
NRSN 1.23 -0.03(-2.38%)
Will NRSN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for NRSN based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for NRSN
NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease
NeuroSense and Genetika+ to collaborate in drug development for Alzheimer's
NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting
NeuroSense reports Phase 2b neurology results of PrimeC
NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024